Report cover image

Global Fibromyalgia Antidepressant Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 197 Pages
SKU # APRC20361782

Description

Summary

According to APO Research, The global Fibromyalgia Antidepressant market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Fibromyalgia Antidepressant is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Fibromyalgia Antidepressant is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Fibromyalgia Antidepressant is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Fibromyalgia Antidepressant is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Fibromyalgia Antidepressant include Pfizer, AbbVie, Virios Therapeutics, TONIX Pharmaceuticals Holdings, FSD Pharma and Aptinyx, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Fibromyalgia Antidepressant, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Fibromyalgia Antidepressant, also provides the sales of main regions and countries. Of the upcoming market potential for Fibromyalgia Antidepressant, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Fibromyalgia Antidepressant sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Fibromyalgia Antidepressant market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Fibromyalgia Antidepressant sales, projected growth trends, production technology, application and end-user industry.

Fibromyalgia Antidepressant Segment by Company

Pfizer
AbbVie
Virios Therapeutics
TONIX Pharmaceuticals Holdings
FSD Pharma
Aptinyx
Fibromyalgia Antidepressant Segment by Type

Milnacipran HCL
Venlafaxine
Duloxetine HCL
Others
Fibromyalgia Antidepressant Segment by Application

Retail Pharmacies
Online Sales
Drug stores
Hospital Pharmacies
Fibromyalgia Antidepressant Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Fibromyalgia Antidepressant market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Fibromyalgia Antidepressant and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Fibromyalgia Antidepressant.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Fibromyalgia Antidepressant in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Fibromyalgia Antidepressant manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Fibromyalgia Antidepressant sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.

Table of Contents

197 Pages
1 Market Overview
1.1 Product Definition
1.2 Fibromyalgia Antidepressant Market by Type
1.2.1 Global Fibromyalgia Antidepressant Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Milnacipran HCL
1.2.3 Venlafaxine
1.2.4 Duloxetine HCL
1.2.5 Others
1.3 Fibromyalgia Antidepressant Market by Application
1.3.1 Global Fibromyalgia Antidepressant Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Retail Pharmacies
1.3.3 Online Sales
1.3.4 Drug stores
1.3.5 Hospital Pharmacies
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Fibromyalgia Antidepressant Market Dynamics
2.1 Fibromyalgia Antidepressant Industry Trends
2.2 Fibromyalgia Antidepressant Industry Drivers
2.3 Fibromyalgia Antidepressant Industry Opportunities and Challenges
2.4 Fibromyalgia Antidepressant Industry Restraints
3 Global Market Growth Prospects
3.1 Global Fibromyalgia Antidepressant Revenue Estimates and Forecasts (2020-2031)
3.2 Global Fibromyalgia Antidepressant Revenue by Region
3.2.1 Global Fibromyalgia Antidepressant Revenue by Region: 2020 VS 2024 VS 2031
3.2.2 Global Fibromyalgia Antidepressant Revenue by Region (2020-2025)
3.2.3 Global Fibromyalgia Antidepressant Revenue by Region (2026-2031)
3.2.4 Global Fibromyalgia Antidepressant Revenue Market Share by Region (2020-2031)
3.3 Global Fibromyalgia Antidepressant Sales Estimates and Forecasts 2020-2031
3.4 Global Fibromyalgia Antidepressant Sales by Region
3.4.1 Global Fibromyalgia Antidepressant Sales by Region: 2020 VS 2024 VS 2031
3.4.2 Global Fibromyalgia Antidepressant Sales by Region (2020-2025)
3.4.3 Global Fibromyalgia Antidepressant Sales by Region (2026-2031)
3.4.4 Global Fibromyalgia Antidepressant Sales Market Share by Region (2020-2031)
3.5 US & Canada & Mexico
3.6 Europe
3.7 China
3.8 Asia (Excluding China)
3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
4.1 Global Fibromyalgia Antidepressant Revenue by Manufacturers
4.1.1 Global Fibromyalgia Antidepressant Revenue by Manufacturers (2020-2025)
4.1.2 Global Fibromyalgia Antidepressant Revenue Market Share by Manufacturers (2020-2025)
4.1.3 Global Fibromyalgia Antidepressant Manufacturers Revenue Share Top 10 and Top 5 in 2024
4.2 Global Fibromyalgia Antidepressant Sales by Manufacturers
4.2.1 Global Fibromyalgia Antidepressant Sales by Manufacturers (2020-2025)
4.2.2 Global Fibromyalgia Antidepressant Sales Market Share by Manufacturers (2020-2025)
4.2.3 Global Fibromyalgia Antidepressant Manufacturers Sales Share Top 10 and Top 5 in 2024
4.3 Global Fibromyalgia Antidepressant Sales Price by Manufacturers (2020-2025)
4.4 Global Fibromyalgia Antidepressant Key Manufacturers Ranking, 2023 VS 2024 VS 2025
4.5 Global Fibromyalgia Antidepressant Key Manufacturers Manufacturing Sites & Headquarters
4.6 Global Fibromyalgia Antidepressant Manufacturers, Product Type & Application
4.7 Global Fibromyalgia Antidepressant Manufacturers' Establishment Date
4.8 Market Competitive Analysis
4.8.1 Global Fibromyalgia Antidepressant Market CR5 and HHI
4.8.2 2024 Fibromyalgia Antidepressant Tier 1, Tier 2, and Tier 3
5 Fibromyalgia Antidepressant Market by Type
5.1 Global Fibromyalgia Antidepressant Revenue by Type
5.1.1 Global Fibromyalgia Antidepressant Revenue by Type (2020 VS 2024 VS 2031)
5.1.2 Global Fibromyalgia Antidepressant Revenue by Type (2020-2031) & (US$ Million)
5.1.3 Global Fibromyalgia Antidepressant Revenue Market Share by Type (2020-2031)
5.2 Global Fibromyalgia Antidepressant Sales by Type
5.2.1 Global Fibromyalgia Antidepressant Sales by Type (2020 VS 2024 VS 2031)
5.2.2 Global Fibromyalgia Antidepressant Sales by Type (2020-2031) & (K Units)
5.2.3 Global Fibromyalgia Antidepressant Sales Market Share by Type (2020-2031)
5.3 Global Fibromyalgia Antidepressant Price by Type
6 Fibromyalgia Antidepressant Market by Application
6.1 Global Fibromyalgia Antidepressant Revenue by Application
6.1.1 Global Fibromyalgia Antidepressant Revenue by Application (2020 VS 2024 VS 2031)
6.1.2 Global Fibromyalgia Antidepressant Revenue by Application (2020-2031) & (US$ Million)
6.1.3 Global Fibromyalgia Antidepressant Revenue Market Share by Application (2020-2031)
6.2 Global Fibromyalgia Antidepressant Sales by Application
6.2.1 Global Fibromyalgia Antidepressant Sales by Application (2020 VS 2024 VS 2031)
6.2.2 Global Fibromyalgia Antidepressant Sales by Application (2020-2031) & (K Units)
6.2.3 Global Fibromyalgia Antidepressant Sales Market Share by Application (2020-2031)
6.3 Global Fibromyalgia Antidepressant Price by Application
7 Company Profiles
7.1 Pfizer
7.1.1 Pfizer Comapny Information
7.1.2 Pfizer Business Overview
7.1.3 Pfizer Fibromyalgia Antidepressant Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 Pfizer Fibromyalgia Antidepressant Product Portfolio
7.1.5 Pfizer Recent Developments
7.2 AbbVie
7.2.1 AbbVie Comapny Information
7.2.2 AbbVie Business Overview
7.2.3 AbbVie Fibromyalgia Antidepressant Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 AbbVie Fibromyalgia Antidepressant Product Portfolio
7.2.5 AbbVie Recent Developments
7.3 Virios Therapeutics
7.3.1 Virios Therapeutics Comapny Information
7.3.2 Virios Therapeutics Business Overview
7.3.3 Virios Therapeutics Fibromyalgia Antidepressant Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 Virios Therapeutics Fibromyalgia Antidepressant Product Portfolio
7.3.5 Virios Therapeutics Recent Developments
7.4 TONIX Pharmaceuticals Holdings
7.4.1 TONIX Pharmaceuticals Holdings Comapny Information
7.4.2 TONIX Pharmaceuticals Holdings Business Overview
7.4.3 TONIX Pharmaceuticals Holdings Fibromyalgia Antidepressant Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 TONIX Pharmaceuticals Holdings Fibromyalgia Antidepressant Product Portfolio
7.4.5 TONIX Pharmaceuticals Holdings Recent Developments
7.5 FSD Pharma
7.5.1 FSD Pharma Comapny Information
7.5.2 FSD Pharma Business Overview
7.5.3 FSD Pharma Fibromyalgia Antidepressant Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 FSD Pharma Fibromyalgia Antidepressant Product Portfolio
7.5.5 FSD Pharma Recent Developments
7.6 Aptinyx
7.6.1 Aptinyx Comapny Information
7.6.2 Aptinyx Business Overview
7.6.3 Aptinyx Fibromyalgia Antidepressant Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 Aptinyx Fibromyalgia Antidepressant Product Portfolio
7.6.5 Aptinyx Recent Developments
8 North America
8.1 North America Fibromyalgia Antidepressant Market Size by Type
8.1.1 North America Fibromyalgia Antidepressant Revenue by Type (2020-2031)
8.1.2 North America Fibromyalgia Antidepressant Sales by Type (2020-2031)
8.1.3 North America Fibromyalgia Antidepressant Price by Type (2020-2031)
8.2 North America Fibromyalgia Antidepressant Market Size by Application
8.2.1 North America Fibromyalgia Antidepressant Revenue by Application (2020-2031)
8.2.2 North America Fibromyalgia Antidepressant Sales by Application (2020-2031)
8.2.3 North America Fibromyalgia Antidepressant Price by Application (2020-2031)
8.3 North America Fibromyalgia Antidepressant Market Size by Country
8.3.1 North America Fibromyalgia Antidepressant Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
8.3.2 North America Fibromyalgia Antidepressant Sales by Country (2020 VS 2024 VS 2031)
8.3.3 North America Fibromyalgia Antidepressant Price by Country (2020-2031)
8.3.4 United States
8.3.5 Canada
9 Europe
9.1 Europe Fibromyalgia Antidepressant Market Size by Type
9.1.1 Europe Fibromyalgia Antidepressant Revenue by Type (2020-2031)
9.1.2 Europe Fibromyalgia Antidepressant Sales by Type (2020-2031)
9.1.3 Europe Fibromyalgia Antidepressant Price by Type (2020-2031)
9.2 Europe Fibromyalgia Antidepressant Market Size by Application
9.2.1 Europe Fibromyalgia Antidepressant Revenue by Application (2020-2031)
9.2.2 Europe Fibromyalgia Antidepressant Sales by Application (2020-2031)
9.2.3 Europe Fibromyalgia Antidepressant Price by Application (2020-2031)
9.3 Europe Fibromyalgia Antidepressant Market Size by Country
9.3.1 Europe Fibromyalgia Antidepressant Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
9.3.2 Europe Fibromyalgia Antidepressant Sales by Country (2020 VS 2024 VS 2031)
9.3.3 Europe Fibromyalgia Antidepressant Price by Country (2020-2031)
9.3.4 Germany
9.3.5 France
9.3.6 U.K.
9.3.7 Italy
9.3.8 Netherlands
9.3.9 Nordic Countries
10 China
10.1 China Fibromyalgia Antidepressant Market Size by Type
10.1.1 China Fibromyalgia Antidepressant Revenue by Type (2020-2031)
10.1.2 China Fibromyalgia Antidepressant Sales by Type (2020-2031)
10.1.3 China Fibromyalgia Antidepressant Price by Type (2020-2031)
10.2 China Fibromyalgia Antidepressant Market Size by Application
10.2.1 China Fibromyalgia Antidepressant Revenue by Application (2020-2031)
10.2.2 China Fibromyalgia Antidepressant Sales by Application (2020-2031)
10.2.3 China Fibromyalgia Antidepressant Price by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Fibromyalgia Antidepressant Market Size by Type
11.1.1 Asia Fibromyalgia Antidepressant Revenue by Type (2020-2031)
11.1.2 Asia Fibromyalgia Antidepressant Sales by Type (2020-2031)
11.1.3 Asia Fibromyalgia Antidepressant Price by Type (2020-2031)
11.2 Asia Fibromyalgia Antidepressant Market Size by Application
11.2.1 Asia Fibromyalgia Antidepressant Revenue by Application (2020-2031)
11.2.2 Asia Fibromyalgia Antidepressant Sales by Application (2020-2031)
11.2.3 Asia Fibromyalgia Antidepressant Price by Application (2020-2031)
11.3 Asia Fibromyalgia Antidepressant Market Size by Country
11.3.1 Asia Fibromyalgia Antidepressant Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
11.3.2 Asia Fibromyalgia Antidepressant Sales by Country (2020 VS 2024 VS 2031)
11.3.3 Asia Fibromyalgia Antidepressant Price by Country (2020-2031)
11.3.4 Japan
11.3.5 South Korea
11.3.6 India
11.3.7 Australia
11.3.8 Taiwan
11.3.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Fibromyalgia Antidepressant Market Size by Type
12.1.1 SAMEA Fibromyalgia Antidepressant Revenue by Type (2020-2031)
12.1.2 SAMEA Fibromyalgia Antidepressant Sales by Type (2020-2031)
12.1.3 SAMEA Fibromyalgia Antidepressant Price by Type (2020-2031)
12.2 SAMEA Fibromyalgia Antidepressant Market Size by Application
12.2.1 SAMEA Fibromyalgia Antidepressant Revenue by Application (2020-2031)
12.2.2 SAMEA Fibromyalgia Antidepressant Sales by Application (2020-2031)
12.2.3 SAMEA Fibromyalgia Antidepressant Price by Application (2020-2031)
12.3 SAMEA Fibromyalgia Antidepressant Market Size by Country
12.3.1 SAMEA Fibromyalgia Antidepressant Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
12.3.2 SAMEA Fibromyalgia Antidepressant Sales by Country (2020 VS 2024 VS 2031)
12.3.3 SAMEA Fibromyalgia Antidepressant Price by Country (2020-2031)
12.3.4 Brazil
12.3.5 Argentina
12.3.6 Chile
12.3.7 Colombia
12.3.8 Peru
12.3.9 Saudi Arabia
12.3.10 Israel
12.3.11 UAE
12.3.12 Turkey
12.3.13 Iran
12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
13.1 Fibromyalgia Antidepressant Value Chain Analysis
13.1.1 Fibromyalgia Antidepressant Key Raw Materials
13.1.2 Raw Materials Key Suppliers
13.1.3 Manufacturing Cost Structure
13.1.4 Fibromyalgia Antidepressant Production Mode & Process
13.2 Fibromyalgia Antidepressant Sales Channels Analysis
13.2.1 Direct Comparison with Distribution Share
13.2.2 Fibromyalgia Antidepressant Distributors
13.2.3 Fibromyalgia Antidepressant Customers
14 Concluding Insights
15 Appendix
15.1 Reasons for Doing This Study
15.2 Research Methodology
15.3 Research Process
15.4 Authors List of This Report
15.5 Data Source
15.5.1 Secondary Sources
15.5.2 Primary Sources
15.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.